Prostate cancer

Oncology

In this interview with pharmaphorum, J&J's Henar Hevia and Carolyn Sousa, share their some of the company's data wins at the show and talk trends.

News

ASCO today brings good news for patients with localised prostate cancer, as early use of J&J's ARPI offers a 19 month increase in median survival.

News

The UK's National Screening Committee has concluded that the harms of widespread prostate cancer screening would outweigh its benefits.

News

Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.

News

The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.

News

A German study has stoked debate about the merits of screening for prostate cancer, which is lagging behind breast cancer screening in Europe.